investorscraft@gmail.com

Intrinsic Value of Halozyme Therapeutics, Inc. (HALO)

Previous Close$38.61
Intrinsic Value
Upside potential
Previous Close
$38.61

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-09-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %48.9NaN
Revenue, $660NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m393NaN
Operating income, $m268NaN
EBITDA, $m326NaN
Interest expense (income), $mNaN
Earnings before tax, $m249NaN
Tax expense, $m47NaN
Net income, $m202NaN

BALANCE SHEET

Cash and short-term investments, $m363NaN
Total assets, $m1842NaN
Adjusted assets (=assets-cash), $m1479NaN
Average production assets, $m520NaN
Working capital, $m608NaN
Total debt, $m1506NaN
Total liabilities, $m1672NaN
Total equity, $m170NaN
Debt-to-equity ratio8.870NaN
Adjusted equity ratio-0.121NaN

CASH FLOW

Net income, $m202NaN
Depreciation, amort., depletion, $m59NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m240NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m21NaN
Free cash flow, $m219NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m608
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount